Novartis | NOVN - Ebitda


Novartis reported $5.3B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Alcon AG USD 795M 478M Mar/2026
Almirall EUR 114.07M 60.37M Dec/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Autolus Therapeutics Ltd USD -70.08M 11.23M Sep/2025
Bayer EUR 4.45B 2.49B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Fresenius EUR 951M 283M Mar/2026
Fresenius Medical Care EUR 824M 250M Mar/2026
Genmab DKK 186M 291M Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
GRIFOLS EUR 347.45M 210K Dec/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
J&J USD 8.27B 1.08B Mar/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.53B 87M Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Novartis USD 5.41B 431M Mar/2026
Novo Nordisk DKK 34.72B 2.57B Mar/2026
Orion EUR 191.9M 61.5M Jun/2026
Pfizer USD 5.99B 5.23B Mar/2026
Philips EUR 567M 233M Mar/2026
Recordati EUR 283.58M 36.43M Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
UCB EUR 1.6B 570M Dec/2025